MA26748A1 - Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation - Google Patents

Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation

Info

Publication number: MA26748A1
Authority: MA; Morocco
Prior art keywords: tetrahydrobenzo; preparation; medicaments containing; azepine derivatives; azepine
Prior art date: 1999-08-06

Application number

MA26033A

Other languages

English (en)

Inventor

Binggeli Alfred

Mutel Vincent

Wilhelm Maurice

Adam Geo

Maerki Hans-Peter

Wostl Wolfgang

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-06

Filing date

2000-08-01

Publication date

2004-12-20

2000-08-01 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26748A1 publication Critical patent/MA26748A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Addiction (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

MA26033A 1999-08-06 2000-08-01 Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation MA26748A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99115557		1999-08-06

Publications (1)

Publication Number	Publication Date
MA26748A1 true MA26748A1 (fr)	2004-12-20

Family

ID=8238742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26033A MA26748A1 (fr)	1999-08-06	2000-08-01	Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation

Country Status (27)

Country	Link
US (1)	US6218385B1 (fr)
JP (1)	JP3260350B2 (fr)
KR (1)	KR100390116B1 (fr)
CN (1)	CN1146455C (fr)
AR (1)	AR025035A1 (fr)
AT (1)	ATE254614T1 (fr)
AU (1)	AU774485B2 (fr)
BR (1)	BR0003375A (fr)
CA (1)	CA2314798A1 (fr)
CO (1)	CO5180625A1 (fr)
DE (1)	DE60006618T2 (fr)
ES (1)	ES2209728T3 (fr)
HR (1)	HRP20000520A2 (fr)
HU (1)	HUP0003112A3 (fr)
ID (1)	ID26743A (fr)
IL (1)	IL137688A0 (fr)
MA (1)	MA26748A1 (fr)
NO (1)	NO20003966L (fr)
NZ (1)	NZ506096A (fr)
PE (1)	PE20010467A1 (fr)
PL (1)	PL341890A1 (fr)
RU (1)	RU2240317C2 (fr)
SG (1)	SG93251A1 (fr)
TR (1)	TR200002298A2 (fr)
UY (1)	UY26276A1 (fr)
YU (1)	YU49700A (fr)
ZA (1)	ZA200003927B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100545906B1 (ko) *	2000-12-22	2006-01-26	에프. 호프만-라 로슈 아게	ｍＧｌｕＲ 1 길항물질로서의 테트라하이드로-(벤조 또는티에노)-아제핀-피라진 및 트리아진 유도체
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
ATE441417T1 (de) *	2002-12-20	2009-09-15	Glaxo Group Ltd	Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
SI2332921T1 (sl) *	2003-06-17	2016-06-30	Arena Pharmaceuticals, Inc.	8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid
US7704993B2 (en) *	2003-06-17	2010-04-27	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042491A1 (fr) *	2003-10-22	2005-05-12	Arena Pharmaceuticals, Inc.	Derives de benzazepine et methodes de prophylaxie ou traitement de maladies associees au recepteur 5ht2c
WO2005042490A1 (fr) *	2003-10-22	2005-05-12	Arena Pharmaceuticals, Inc.	Derives de benzazepine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5-ht2c
CA2589988C (fr)	2004-12-21	2017-02-14	Arena Pharmaceuticals, Inc.	Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
PT1833473E (pt)	2004-12-23	2009-12-17	Arena Pharm Inc	Composições de modulador de receptor 5ht2c e métodos de utilização
EP2258359A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (fr)	2005-10-31	2011-04-27	Braincells, Inc.	Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2518053A1 (fr)	2006-04-03	2012-10-31	Arena Pharmaceuticals, Inc.	Procédé de préparation de la 8-chloro-1-méthyl-2,3,4,5-tétrahydro-1H-3-benzazépine
CA2651862A1 (fr)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenese induite par le recepteur 5ht
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
EP1873527A1 (fr) *	2006-06-30	2008-01-02	Schwarz Pharma Ag	Procédé d'identification des modulateurs CRMP
WO2008030651A1 (fr)	2006-09-08	2008-03-13	Braincells, Inc.	Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
HUE032743T2 (en)	2006-11-22	2017-10-30	Clinical Res Ass Llc	A method for treating Down syndrome, fragilis X syndrome and autism
EP2099743B1 (fr) *	2006-12-05	2014-08-27	Arena Pharmaceuticals, Inc.	Procédés de préparation de (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazépine et intermédiaires de celle-ci
TW200845978A (en) *	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP5491421B2 (ja)	2008-03-04	2014-05-14	アリーナファーマシューティカルズ，インコーポレイテッド	５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN102648170A (zh)	2009-06-18	2012-08-22	艾尼纳制药公司	制备5-ht2c受体激动剂的方法
WO2011109398A2 (fr)	2010-03-02	2011-09-09	President And Fellows Of Harvard College	Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique
WO2011150380A1 (fr)	2010-05-28	2011-12-01	Xenoport, Inc.	Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés
WO2011153206A1 (fr)	2010-06-02	2011-12-08	Arena Pharmaceuticals, Inc.	Procédés pour la préparation d'agonistes du récepteur 5-ht2c
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
MX2013002422A (es)	2010-09-01	2013-05-17	Arena Pharm Inc	Sales de lorcaserina con acidos opticamente activos.
WO2012030957A2 (fr)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Sels non hygroscopiques d'agonistes de 5-ht2c
CN103347523A (zh)	2010-09-01	2013-10-09	艾尼纳制药公司	向具有肾损伤的个体给药氯卡色林
KR20180118801A (ko)	2010-09-01	2018-10-31	에자이 알앤드디 매니지먼트 가부시키가이샤	체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
WO2014058441A1 (fr)	2012-10-09	2014-04-17	Arena Pharmaceuticals, Inc.	Procédé de gestion du poids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4206210A (en) *	1977-01-19	1980-06-03	Smithkline Corporation	Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
EP0556310B1 (fr) *	1990-11-06	1995-07-05	Pfizer Inc.	Derives de quinazolines utiles pour stimuler l'activite antitumorale
US5241065A (en) *	1992-02-25	1993-08-31	Schering Corporation	2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
AU678503B2 (en) *	1993-09-24	1997-05-29	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds and their use as squalene synthetase inhibitors

2000
- 2000-07-27 DE DE60006618T patent/DE60006618T2/de not_active Expired - Fee Related
- 2000-07-27 ES ES00116091T patent/ES2209728T3/es not_active Expired - Lifetime
- 2000-07-27 AT AT00116091T patent/ATE254614T1/de not_active IP Right Cessation
- 2000-08-01 MA MA26033A patent/MA26748A1/fr unknown
- 2000-08-01 CA CA002314798A patent/CA2314798A1/fr not_active Abandoned
- 2000-08-01 NZ NZ506096A patent/NZ506096A/xx unknown
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/hr not_active Application Discontinuation
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-02 ID IDP20000655A patent/ID26743A/id unknown
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/es not_active Application Discontinuation
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/xx unknown
- 2000-08-03 CO CO00058410A patent/CO5180625A1/es not_active Application Discontinuation
- 2000-08-03 IL IL13768800A patent/IL137688A0/xx unknown
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/hu unknown
- 2000-08-04 NO NO20003966A patent/NO20003966L/no not_active Application Discontinuation
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/ko not_active Expired - Fee Related
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/ja not_active Expired - Fee Related
- 2000-08-04 TR TR2000/02298A patent/TR200002298A2/xx unknown
- 2000-08-04 CN CNB001225235A patent/CN1146455C/zh not_active Expired - Fee Related
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/ru not_active IP Right Cessation
- 2000-08-04 AR ARP000104022A patent/AR025035A1/es not_active Application Discontinuation
- 2000-08-04 UY UY26276A patent/UY26276A1/es not_active Application Discontinuation
- 2000-08-07 YU YU49700A patent/YU49700A/sh unknown
- 2000-08-07 PL PL00341890A patent/PL341890A1/xx unknown
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
HRP20000520A2 (en)	2001-06-30
DE60006618D1 (de)	2003-12-24
PL341890A1 (en)	2001-02-12
BR0003375A (pt)	2001-03-13
UY26276A1 (es)	2000-10-31
HUP0003112A2 (hu)	2002-11-28
KR100390116B1 (ko)	2003-07-04
CN1283623A (zh)	2001-02-14
ES2209728T3 (es)	2004-07-01
AR025035A1 (es)	2002-11-06
IL137688A0 (en)	2001-10-31
DE60006618T2 (de)	2004-09-23
NZ506096A (en)	2002-08-28
ATE254614T1 (de)	2003-12-15
TR200002298A3 (tr)	2001-03-21
YU49700A (sh)	2003-04-30
CO5180625A1 (es)	2002-07-30
CN1146455C (zh)	2004-04-21
ID26743A (id)	2001-02-08
PE20010467A1 (es)	2001-04-17
AU774485B2 (en)	2004-07-01
ZA200003927B (en)	2001-02-06
NO20003966L (no)	2001-02-07
TR200002298A2 (tr)	2001-03-21
NO20003966D0 (no)	2000-08-04
US6218385B1 (en)	2001-04-17
RU2240317C2 (ru)	2004-11-20
HU0003112D0 (en)	2000-10-28
JP2001089472A (ja)	2001-04-03
SG93251A1 (en)	2002-12-17
JP3260350B2 (ja)	2002-02-25
AU4897900A (en)	2001-02-08
CA2314798A1 (fr)	2001-02-06
HUP0003112A3 (en)	2003-07-28
KR20010082510A (ko)	2001-08-30

Publication	Publication Date	Title
MA26748A1 (fr)	2004-12-20	Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation
MA26425A1 (fr)	2004-12-20	Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26653A1 (fr)	2004-12-20	Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA23831A1 (fr)	1996-10-01	Derives de quinazoline, procede pour leur preparation et composition les contenant
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26680A1 (fr)	2004-12-20	Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr)	2004-12-20	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26505A1 (fr)	2004-12-20	Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26465A1 (fr)	2004-12-20	Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26415A1 (fr)	2004-12-20	Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26558A1 (fr)	2004-12-20	Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr)	1997-04-18	Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26424A1 (fr)	2004-12-20	Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26614A1 (fr)	2004-12-20	Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2783246B1 (fr)	2000-11-17	Derives d'azetidine, leur preparation et les medicaments les contenant
MA26479A1 (fr)	2004-12-20	Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25433A1 (fr)	2002-04-01	Derives d'arylmethyl-carbonylamino-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux
HUP0203294A3 (en)	2003-03-28	Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
MA26526A1 (fr)	2004-12-20	Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26740A1 (fr)	2004-12-20	Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26567A1 (fr)	2004-12-20	Trifluoromethylethers cycliques a fonction piperidinylaminomethule, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26501A1 (fr)	2004-12-20	Derives de quinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant